Scholarlink

Background <p>The incorporation of nanomaterials and nanomedicine is set to revolutionize biomedical research by offering novel tools and methodologies to tackle significant issues in healthcare. Ovarian cancer, marked by its subtle onset and late diagnosis, continues to provide a significant challenge in cancer treatment, requiring novel strategies to enhance patient outcomes.</p> Objective <p>The present study primarily focused on the synthesis and characterization of nerolidol-functionalized graphene oxide (GO), iron (II) nitrate (Fe), and nickel nitrate (Ni) nanoparticles (GO-Fe-Ni/Nerolidol NPs) and the assessment of their anticancer efficacy against the ovarian cancer cell line.</p> Methodology <p>The synthesized GO-Fe-Ni/Nerolidol NPs were characterized through several methods, including X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), dynamic light scattering (DLS), UV-visible spectroscopy, and photoluminescence (PL) analyses. The viability of ovarian cancer A2780 cells treated with GO-Fe-Ni/Nerolidol NPs was assessed using an MTT test. The dual staining approach was utilized to investigate apoptosis in GO-Fe-Ni/Nerolidol NPs-treated A2780 cells. The concentrations of oxidative stress indicators in the NPs-treated cells were analyzed utilizing kits. </p> Results <p>The outcomes of the characterization assays have exhibited the successful synthesis of GO-Fe-Ni/Nerolidol NPs. The XRD results validated the purity and crystalline structure of the NPs. The SEM and EDAX investigations revealed that the produced NPs exhibit a rod-like morphology with the presence of several elements. The DLS analysis indicated that the NPs possess an average size of 138.30&#xa0;nm. The MTT assay findings indicated that the treatment with GO-Fe-Ni/Nerolidol NPs remarkably inhibited the A2780 cell growth. Furthermore, the LDH release assay has evidenced that the NPs treatment considerably increased the LDH enzyme activity in the A2780 cells. The results of dual staining indicated an elevated apoptotic incidence in the NPs-treated A2780 cells. Furthermore, it increased the MDA levels while reducing antioxidant concentrations in the A2780 cells.</p> Conclusion <p>The current work demonstrates that GO-Fe-Ni/Nerolidol NPs exert potent anticancer effects against ovarian cancer cells. By integrating the high surface area of GO, the magnetic and catalytic properties of Fe and Ni, and the natural therapeutic bioactivity of nerolidol, this unique multicomponent platform achieves synergistic oxidative stress induction and apoptosis, presenting a highly promising candidate for targeted ovarian cancer therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Nerolidol-Loaded Graphene Oxide/Iron Nitrate/Nickel Nitrate Nanoparticles Induce Oxidative Stress-Mediated Apoptosis in Ovarian Cancer A2780 Cells

  • 期刊论文

  • 发表日期：

    2026年6月22日

查看全文
  • Jingjing Li,
  • Wei Chen,
  • Cuiling Gao

摘要

Background

The incorporation of nanomaterials and nanomedicine is set to revolutionize biomedical research by offering novel tools and methodologies to tackle significant issues in healthcare. Ovarian cancer, marked by its subtle onset and late diagnosis, continues to provide a significant challenge in cancer treatment, requiring novel strategies to enhance patient outcomes.

Objective

The present study primarily focused on the synthesis and characterization of nerolidol-functionalized graphene oxide (GO), iron (II) nitrate (Fe), and nickel nitrate (Ni) nanoparticles (GO-Fe-Ni/Nerolidol NPs) and the assessment of their anticancer efficacy against the ovarian cancer cell line.

Methodology

The synthesized GO-Fe-Ni/Nerolidol NPs were characterized through several methods, including X-ray diffraction (XRD), scanning electron microscopy (SEM), transmission electron microscopy (TEM), dynamic light scattering (DLS), UV-visible spectroscopy, and photoluminescence (PL) analyses. The viability of ovarian cancer A2780 cells treated with GO-Fe-Ni/Nerolidol NPs was assessed using an MTT test. The dual staining approach was utilized to investigate apoptosis in GO-Fe-Ni/Nerolidol NPs-treated A2780 cells. The concentrations of oxidative stress indicators in the NPs-treated cells were analyzed utilizing kits.

Results

The outcomes of the characterization assays have exhibited the successful synthesis of GO-Fe-Ni/Nerolidol NPs. The XRD results validated the purity and crystalline structure of the NPs. The SEM and EDAX investigations revealed that the produced NPs exhibit a rod-like morphology with the presence of several elements. The DLS analysis indicated that the NPs possess an average size of 138.30 nm. The MTT assay findings indicated that the treatment with GO-Fe-Ni/Nerolidol NPs remarkably inhibited the A2780 cell growth. Furthermore, the LDH release assay has evidenced that the NPs treatment considerably increased the LDH enzyme activity in the A2780 cells. The results of dual staining indicated an elevated apoptotic incidence in the NPs-treated A2780 cells. Furthermore, it increased the MDA levels while reducing antioxidant concentrations in the A2780 cells.

Conclusion

The current work demonstrates that GO-Fe-Ni/Nerolidol NPs exert potent anticancer effects against ovarian cancer cells. By integrating the high surface area of GO, the magnetic and catalytic properties of Fe and Ni, and the natural therapeutic bioactivity of nerolidol, this unique multicomponent platform achieves synergistic oxidative stress induction and apoptosis, presenting a highly promising candidate for targeted ovarian cancer therapy.